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ABSTRACT 70 
Background & Aims: Non-endoscopic methods for diagnosis and surveillance of 71 
Barrett’s esophagus (BE) and eosinophilic esophagitis are needed. Cytosponge is a 72 
minimally invasive device for esophageal cell sampling. We aimed to assess safety 73 
and acceptability of this device. 74 
 75 
Methods: We collected data from 5 prospective trials from patients with reflux 76 
disease, BE, or eosinophilic esophagitis in primary and secondary care. We analyzed 77 
data from 2,672 Cytosponge procedures, performed in 2,418 individuals from 2008 78 
through 2017. Acceptability of the Cytosponge and subsequent endoscopy were 79 
calculated using the visual analogue scale (VAS; score of 0 for the lowest and 10 for 80 
highest level of acceptability) and compared using a Mann Whitney test. The number 81 
of attempts, failures in swallowing the device, and occurrence of adverse events 82 
were analyzed. Risk factors for failure in swallowing were analyzed using a 83 
multivariate regression model. 84 
 85 
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Results: There were 2 adverse events related to the device: a pharyngeal bleed and 86 
1 case of detachment (<1:2000). The median acceptability score for Cytosponge was 87 
6.0 (inter-quartile range [IQR], 5.0–8.0), which was higher than for endoscopy without 88 
sedation (median 5.0, IQR, 3.0–7.0; P<.001) and lower than for endoscopy with 89 
sedation (median 8.0, IQR, 5.0–9.0; P<.001). Nearly all patients (96.5%) successfully 90 
swallowed the Cytosponge, most often on the first swallow attempt (90.1%). Failure 91 
to swallow the device was more likely to occur in secondary care (odds ratio, 5.13, 92 
95% CI, 1.48–17.79; P<.01). 93 
 94 
Conclusion: Cytosponge is safe and well accepted for esophageal tissue collection, 95 
in a variety of health care settings. 96 
KEY WORDS: EoE; clinical trials; acceptability; cytology 97 
 98 
 99 
 100 
 101 
 102 
 103 
 104 
 105 
INTRODUCTION 106 
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Two chronic esophageal diseases - Barrett’s esophagus (BE) and eosinophilic 107 
esophagitis (EoE) - have become emerging issues in the public health over the last 108 
several decades1,2,3.  109 
BE develops on the background of long-standing gastro-esophageal reflux 110 
disease (GERD) and is defined as a metaplastic change in the esophageal lining, from 111 
a squamous-type epithelium to a specialized columnar epithelium. The estimated 112 
population prevalence of BE is 1- 2%4. BE is a major risk factor for esophageal 113 
adenocarcinoma (EAC) - a cancer with rapidly increasing incidence in the Western 114 
world5. Patients with chronic GERD and other risk factors (male sex, age of ≥ 50 years, 115 
white race, family history of BE or EAC) may be offered endoscopic screening for the 116 
presence of BE6, however most BE cases remain undiagnosed. Patients with the 117 
benefit of a BE diagnosis undergo endoscopic surveillance with the aim to identify 118 
neoplastic changes within BE segment at the earliest possible stage7,8,9. Such patients 119 
are candidates for endoscopic treatment with either endoscopic mucosal resection 120 
(EMR) or radiofrequency ablation (RFA)10,11 with excellent survival results for intra-121 
mucosal disease12.  122 
EoE, on the other hand, is a relatively newly defined immune-mediated disease 123 
characterized by predominant eosinophilic inflammation of the esophagus (a peak 124 
count of ≥ 15 eosinophil per high-power field of biopsy tissue)13. EoE is seen 125 
predominantly in younger men, however it affects all age groups and both sexes14,15. 126 
It is one of the most common condition in adult patients leading to food bolus impaction. 127 
As with BE, most cases of EoE are undiagnosed, and its incidence rate is reaching up 128 
to 12.8 /100,000 / year in some regions of the US16. The aim of diagnosis and treatment 129 
is to control the symptoms, resolve esophageal eosinophilia, and reduce 130 
complications.  131 
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Although the nature of these two entities is highly disparate, both require long-132 
term, endoscopic monitoring and repeated collection of mucosal samples to optimize 133 
and monitor the treatment. To perform systematic screening and surveillance for these 134 
conditions would constitute a huge burden on health care systems. A survey study 135 
analyzing trends in endoscopic volume in the US showed that there was a 54% 136 
increase in upper GI endoscopy between 2000 and 2009, with an estimated number 137 
of 6.9 million of these procedures performed in 200917. The rising incidence of BE and 138 
EoE may have contributed to these numbers. Patients with EoE alone have an 139 
estimated annual health-care cost of as much as $1.4 billion in the US18. 140 
While diagnostic esophagogastroduodenoscopy (EGD) is considered to be a 141 
safe procedure, it is not devoid of complications. The overall mortality rates for EGD 142 
are ranging from none to 1 in 2,000 in various studies19. Perforation, a potentially life-143 
threatening complication, is reported to occur from 1 in every 2,500 to 1 in every 11,000 144 
procedures20,21. Moreover, many of the EGDs in the US and Europe are performed 145 
under sedation, exposing patients to additional risks. These include cardiopulmonary 146 
complications, which account for as much as 60% of endoscopy adverse events and 147 
an incidence ranging between 1 in 170 and 1 in 10,00022. 148 
Therefore, new, less invasive methods of esophageal mucosal sampling are 149 
being investigated. Cytosponge® is a minimally invasive cell collection device that 150 
consists of a 30-mm polyurethane sponge, contained within a capsule attached to a 151 
string. When withdrawn, the device collects esophageal cells for analysis (Figure 1A). 152 
Cytosponge has already been successfully used in several studies to identify BE and 153 
EoE23,24,25. The cells retrieved from the sponge are spun down and embedded to 154 
produce a pseudo-biopsy suitable for routine laboratory analysis (Figure 1B-D). To aid 155 
the identification of BE, the histopathological analysis is coupled with a diagnostic 156 
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biomarker, Trefoil Factor-3 (TFF-3); Figure 1C. Of note, the utility of the Cytosponge 157 
goes beyond the confines of BE and EoE diagnosis since a range of pathologies 158 
affecting the esophagus and proximal stomach, such as esophageal candidiasis, 159 
esophageal ulcers, H.pylori infection, intestinal metaplasia at the cardia and viral 160 
esophagitis can also be diagnosed26.  161 
The aim of this study was to combine data from 5 large trials on Cytosponge 162 
performed in patients with chronic GERD, BE and EoE in 3 different countries (UK, 163 
USA and Australia) to assess the overall safety and acceptability of this test. 164 
METHODS 165 
Study design and study participants 166 
This was a retrospective, patient-level technical review of prospectively 167 
collected data. Studies included in the analyses were the Barrett’s ESophagus Trial 1 168 
(BEST1)24, BEST225, BEST-Australia, the ongoing BEST2-RFA study 169 
(ClinicalTrials.gov number NCT02106910) and Cytosponge Eosinophilic Esophagitis 170 
study (EoE Study, NCT02114606)23. Principal investigators of each trial shared the 171 
original trial databases. All studies were conducted with the use of Cytosponge 172 
approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). 173 
Briefly, the setting and patients’ eligibility criteria of each study were as follows: 174 
• BEST1: individuals with chronic GERD managed in primary care with long-term PPI 175 
(>3 months).  176 
• BEST2: patients with previously diagnosed BE (cases) and patients with GERD 177 
without BE (control group) referred to the secondary care unit for endoscopy. 178 
• BEST-Australia: patients with chronic GERD symptoms referred for endoscopy in 179 
a secondary care unit.  180 
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• BEST2-RFA: patients with BE with low-grade dysplasia (LGD) or high-grade 181 
dysplasia (HGD), who received radiofrequency ablation (RFA) or are under 182 
surveillance following ablative treatment.  183 
• EoE study: patients with EoE referred for the secondary care unit to undergo 184 
clinically indicated endoscopy.  185 
Exclusion criteria were generally consistent between studies and included bleeding 186 
disorders, known cirrhosis +/- varices, history of esophageal surgery, dysphagia and 187 
esophageal stricture. An overview of study characteristics is presented in Table 1.  188 
Cytosponge Procedure  189 
The Cytosponge was administered in a similar fashion in each trial by trained 190 
research nurses, research fellows or study investigators. All participants were given 191 
the option of having a local anesthetic (1% lignocaine throat spray) before having the 192 
test. After swallowing the device in sitting position, the capsule coating disintegrates 193 
within 5 minutes upon reaching the stomach, revealing a 3-cm diameter spherical 194 
mesh that is withdrawn by pulling the string. Following its retrieval, the string is cut 195 
andthe Cytosponge is immersed in SurePath Preservative Fluid (TriPath Imaging, 196 
Burlington, North Carolina, USA) and kept at 4oC until transported to the laboratory for 197 
processing. Hematoxilin Eosin (H&E) staining and immunohistochemistry for TFF-3 is 198 
then performed on paraffin-embedded Cytosponge specimens by adhering to standard 199 
H&E and TFF3 protocols on a BOND-MAX autostainer (Leica Biosystems, Newcastle 200 
Upon Tyne, UK). 201 
Outcome measures 202 
Acceptability of the Cytosponge and subsequent endoscopy (regardless of 203 
sedation) was recorded using a visual analogue scale (VAS), wherein 10 indicated the 204 
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best and 0 the worst experience27. The acceptability scores were collected immediately 205 
after Cytosponge procedure and after each endoscopy procedure (within 30 minutes). 206 
Patients in secondary care studies (BEST2, BEST-Australia, EoE Study, BEST2-RFA) 207 
underwent the Cytosponge and endoscopy on the same day, whereas patients from 208 
BEST1 (primary care) had their endoscopy scheduled within three weeks and the 209 
acceptability score for endoscopy was not recorded. Number of swallow attempts and 210 
failure in swallowing the Cytosponge were noted. ‘Failure to swallow’ was stated when 211 
the device could not be swallowed despite three attempts. Patients in BEST2 and EoE 212 
study had repeated Cytosponge tests. All serious adverse events (SAE) were reported 213 
in accordance to the Good Clinical Practice guidelines. Minor events, such as sore 214 
throat, were not systematically recorded. 215 
Cytosponge abrasions grading system 216 
An abrasion grading system was introduced to categorize the severity of 217 
abrasions following the Cytosponge procedure. The presence and degree of abrasions 218 
were recorded during subsequent EGD. Abrasions provide useful information on the 219 
most distal passage of the device (important for diagnosing BE) as well as a 220 
comparator with biopsies for the bleeding risk. The grading system is presented in 221 
Figure 2. 222 
Statistical Analysis 223 
Statistics for continuous variables were expressed as medians and interquartile 224 
ranges (IQRs). The Mann-Whitney test was used to compare continuous variables 225 
between groups. The association between failure in swallowing the Cytosponge and 226 
risk factors was analyzed using multivariable regression model. We reported odds 227 
ratios (OR) and 95% confidence intervals (CI) adjusted for patient’s sex, study setting, 228 
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BMI and indication. All statistical tests were two-sided. For all analyses, P value of less 229 
than 0.05 was considered statistically significant. All analyses were performed using R 230 
Statistics version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria).  231 
RESULTS 232 
Patient Demographics 233 
In total, data on 2,418 patients from 5 studies between May 2008 and August 234 
2017 were analyzed. Eighty-four patients were unable to swallow the Cytosponge and 235 
50 were withdrawn due to study eligibility (2.0%), leaving 2,284 patients who 236 
successfully underwent the Cytosponge test (94.5%) and a successful swallow rate of 237 
96.5%. The study cohort comprised of 518 BEST1 patients (21.4%), 1,498 BEST2 238 
patients (62.0%), 224 BEST-Australia patients (9.3%), 76 BEST2-RFA patients (3.1%), 239 
and 102 EoE study patients (4.2%).  240 
There were 1,329 patients with GERD (56.7%), 987 patients with BE (40.8%; 241 
911 from BEST2 and 76 from BEST2-RFA) and 102 patients with EoE (4.2%). The 242 
median age was 62 years (IQR 54-68) and the male to female ratio was 1.7:1.0. The 243 
median body mass index (BMI) was 28.2 kg/m2 (IQR 25.1-31.5), indicating that most 244 
patients were overweight. The median waist-to-hip ratio for females was 0.86 (IQR 245 
0.81-0.91) and for males it was 0.96 (IQR 0.92-0.99). Smoking status was recorded for 246 
1,971 patients. Of these, 809 were reported as lifetime non-smokers (41.0%), 971 as 247 
former smokers (49.2%) and 191 as active smokers (9.7%). More than half of patients 248 
who underwent endoscopy had been diagnosed with hiatus hernia (53.7%). Combined 249 
demographic data is presented in Table 2.  250 
Cytosponge Acceptability 251 
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Overall, 2,672 Cytosponge test were performed, of which 2,289 had 252 
acceptability score recorded (85.7%). The length of the procedure was only recorded 253 
in the BEST-Australia study (n=166; 58 missing), indicating that the median time of the 254 
procedure was 7.0 minutes (range:3.0-9.0). Anesthetic throat spray was only used in 255 
190 cases (7.1%), however, this data was not routinely recorded and is therefore 256 
missing for nearly half of procedures (n=1316, n=49.3%). The endoscopy acceptability 257 
score was not recorded in BEST1 due to the gap between the two procedures which 258 
would make a comparison difficult. Overall, acceptability was recorded for 1,406 259 
endoscopy procedures in 1,221 patients. Therefore, for 2,672 Cytosponge procedures 260 
we had 1,406 corresponding acceptability scores for subsequent endoscopies 261 
(52.6%). Of these, 1,175 endoscopies included data on sedation (96.2%), such that 262 
402 EGD’s were performed without sedation (34.2%) and 773 with sedation (65.8%), 263 
which inevitably affected the rating.  264 
The overall acceptability for the Cytosponge was satisfactory, with a median 265 
score of 6.0 (IQR 5.0-8.0). This was significantly higher when compared to endoscopy 266 
without sedation with median VAS score of 5.0 (IQR 3.0-7.0) (P<0.001), but still 267 
comparatively lower than endoscopy with sedation (VAS 8.0, IQR 5.0-9.0)(P<0.001); 268 
see Figure 3. EoE patients had the highest acceptability for the test (VAS 8.0, IQR 5.1-269 
9.0), as compared to patients with BE [VAS 7.0 (IQR 5.0-8.0)] and GERD [VAS 6.0 270 
(IQR 4.9-8.0)]; P<0.001 for both comparisons. The presence of hiatus hernia did not 271 
influence the acceptability score (P=0.109). Males had higher acceptability than 272 
females [median 7.0 (IQR 5.0-8.0) vs 6.0 (IQR 5.0-8.0), P=0.003], as did patients in 273 
primary care setting, when compared to patients in secondary care (7.0 [IQR 5.0-8.0] 274 
vs. 6.0 [IQR 5.0-8.0], P<0.001). See Figure 4. 275 
Failure to swallow the Cytosponge 276 
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Eighty-four patients failed to swallow the Cytosponge (3.5%). All EoE patients 277 
successfully swallowed the device. The proportion of patients who were unable to 278 
swallow the device was over 2-times higher within BE patients than in GERD patients 279 
(5.7% vs 2.1%) and slightly higher within males as compared to females (3.9% vs 280 
2.7%), however, in a multivariable regression model, the risk of swallow failure in 281 
patients with previously diagnosed BE was not significantly different, when compared 282 
to patients with GERD (OR=0.63, 95%CI 0.35-1.14, P=0.13). Moreover, high BMI and 283 
gender were not associated with different rates of failure in swallowing the device. 284 
Patients examined in secondary care setting were over 5-times more likely to fail 285 
swallowing the Cytosponge, as compared to primary care setting (OR= 5.13, 95% CI 286 
1.48-17.79, P<0.01). Supplementary table 1 presents the multivariable regression 287 
model results. Most successful tests were achieved with the first swallow attempt 288 
(90.1%). 289 
Cytosponge adverse events 290 
Overall, of the 2,672 Cytosponge tests performed, there were 12 SAE reported, 291 
of which only 2 could be directly attributed to the Cytosponge (<1: 2,000). These 292 
included one detachment of the sponge and one pharyngeal bleeding after 293 
Cytosponge withdrawal. The others were related to endoscopic therapy performed 294 
immediately after the Cytosponge test (see Supplementary table 2). As sore throat is 295 
a frequent event following endoscopy, we did not consider it an AE and the data was 296 
not collected systematically across all studies. No late AE, such as strictures have 297 
been reported. 298 
Cytosponge detachment occurred in a 76-year-old male patient with BE in the 299 
BEST2-RFA study at the University of North Carolina. The patient did not report any 300 
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discomfort when the device was retained. Since the Cytosponge test was performed 301 
in the secondary care setting, it was retrieved endoscopically on the same day. The 302 
detached device was found in the pylorus and was successfully retrieved with a Roth 303 
net without further adverse consequences for the patient. 304 
There was one case of mild pharyngeal bleeding in a patient from BEST2 study. 305 
The patient was on warfarin for atrial fibrillation, that was stopped prior to the procedure 306 
(INR was 1.2). The bleeding resolved spontaneously and there was no drop in 307 
Haemoglobin levels. He was hospitalized as a precautionary measure and was 308 
discharged home the next day. 309 
Moreover, there was a single case of variceal bleeding in BEST2 study patient, 310 
however this event was more likely to be related with subsequent endoscopy 311 
procedure than with the Cytosponge. In this case, there was no signs of bleeding after 312 
withdrawal of the device and the subsequent endoscopy (on the same day) revealed 313 
esophageal varices (patient had no previous history of varices). Since there were no 314 
signs of bleeding at that time, endoscopy was performed as per usual practice and the 315 
patient was discharged, however had to be re-admitted in the early hours of the 316 
following day with haematemesis. Gastroscopy was performed again, and 2 bleeding 317 
varices were banded. 318 
Cytosponge abrasions 319 
A Cytosponge abrasions grading system was devised in November 2011. It 320 
categorizes abrasions into five categories based on visual appearance of abrasions 321 
during endoscopy. This grading system was used in BEST2, BEST2-RFA and EoE 322 
Study. Overall, 1,075 Cytosponge procedures were followed by an endoscopy with 323 
abrasion score assessment. In most of the cases (919/1075; 85.5%) Cytosponge 324 
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caused no or only mild abrasions (grade 0-2). Precisely, there were 74 cases with no 325 
abrasions noted after Cytosponge procedure (6.9%), 433 cases of grade 1 abrasions 326 
(40.3%), 412 cases of grade 2 abrasions (38.3%), 132 cases grade 3 abrasions 327 
(12.3%) and only 24 cases (2.2%) of severe post- Cytosponge abrasions (grade 4). 328 
There were no cases of grade 5 abrasions that required endoscopic or surgical 329 
intervention. Of note, Cytosponge abrasions, even at the highest grade of 4, appear 330 
less severe when compared to current standard of care (quadrantic biopsies obtained 331 
every 2 cm - Seattle protocol28), as shown in Figure 2.  332 
DISCUSSION 333 
 This technical review of five large prospective studies on the performance of the 334 
Cytosponge showed that it is a safe procedure with good acceptability ratings. The test 335 
can be safely performed by a nurse in both the primary and secondary care setting, 336 
with minimal risk of AE. The Cytosponge test was feasible when used for screening 337 
purposes (GERD patients with high-risk for BE), as well as for surveillance (EoE and 338 
BE after endoscopic treatment). 339 
Safety is paramount for any procedure especially when being performed in the 340 
primary care setting. Our review showed that of 2,672 Cytosponge procedures there 341 
were only two SAE that could be directly attributed to the device (<1: 2,000) and both 342 
resolved without any ill-effects for the patient. The detachment is the most concerning 343 
risk factor to both clinicians and patients29. However, a retained sponge in the stomach 344 
would not be expected to cause any symptoms as was the case in the patient reported 345 
here. Since objects greater than 2–2.5cm in diameter do not pass through the 346 
pylorus30, we expect the expanded sponge (which has a diameter of 3 cm) to stay in 347 
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the stomach after detachment. In case of this unlikely event, endoscopy retrieval 348 
should be easily arranged. 349 
In a recent perspective article, it was reported that the Cytosponge had been 350 
recalled due to two cases of detachment in the CASE1 study (FDA Recall Z-2123-351 
2016)31. We would like to emphasize that the above article refers to an alternative 352 
prototype device developed by Covidien GI Solutions (now Medtronic), not the original 353 
prototype patented by the Medical Research Council (MRC) UK, which was used in all 354 
the studies reported here. FDA and CE marking of the original device is underway 355 
[Cytosponge received 510(k) clearance from the FDA on November 26, 2014 356 
(K142695)]. 357 
Previous interview-based, quality study on 33 participants with GERD showed 358 
that Cytosponge is acceptable for most participants, as well as being preferred to 359 
endoscopy29. In our study, most patients (79.3%) scored their experience as at least 360 
“neutral” (VAS≥5) and the median VAS score was 6.0 (IQR 5.0-8.0). This was 361 
significantly higher when compared to endoscopy without sedation (VAS 5.0, IQR 3.0-362 
7.0), however lower than endoscopy with sedation (VAS 8.0, IQR 5.0-9.0, P<0.001 for 363 
both comparisons). It must be stressed, that the Cytosponge has other advantages as 364 
a screening tool, when compared to the latter. Endoscopy with sedation is an invasive, 365 
time-consuming procedure (usually several hours including recovery time), that 366 
requires the patient to avoid work and operating machinery for the subsequent 24 367 
hours. Cytosponge can be performed in 5-7 minutes, within a primary care office, and 368 
(usually) does not involve any restrictions for the remaining part of the day.  369 
Our review shows that patients with previously diagnosed BE and EoE have a 370 
higher acceptability rating for Cytosponge as compared to patients with GERD 371 
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(P<0.001). Supposably, these patients are more aware of the importance of 372 
undergoing regular monitoring and are more used to repeated endoscopic 373 
examinations, which might explain the higher degree of acceptability. Patients 374 
examined in the primary care setting (n= 518), had markedly higher acceptance, as 375 
compared to patients examined in the secondary care (n=2,154). The unequal size of 376 
the groups could, however, be a confounding factor. Nevertheless, we postulate that 377 
the more patient-friendly environment and individual approach of a primary care setting 378 
benefits the overall acceptability of the test and it also possible that in secondary care 379 
patients are more keen to undergo the current gold-standard endoscopy procedure. 380 
These results are promising, since the Cytosponge was developed with aim to be a 381 
minimally invasive test for use in a primary-care offices.  382 
Prior to implementation in clinical practice, randomized trial data is required to 383 
fully evaluate the diagnostic yield of Cytosponge and its safety, acceptability and health 384 
economic outcomes. This is currently underway in the Barrett's ESophagus Trial 3 385 
[(BEST3); trial ID ISRCTN68382401], a 10,000-patient cluster randomized controlled 386 
trial which is being conducted in multiple UK primary care surgeries (more information: 387 
https://www.best3trial.org/the-best3-trial, funded by Cancer Research UK). 388 
The main strength of the study is the direct access to original dataset to minimize 389 
missing data and ensure high quality of the statistical analyses. The studies were 390 
undertaken in several countries, for different indications and in different health care 391 
settings, however with the use of same Cytosponge device (design and model) and 392 
standard operating procedure for administration. This study does have some 393 
limitations. There were comparatively fewer acceptability scores recorded for 394 
endoscopy than the Cytosponge. This was because patients enrolled onto the BEST1 395 
trial did not have the acceptability score recorded following endoscopy. Furthermore, 396 
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the VAS scale is a crude measure of acceptability and further quantitative and 397 
qualitative interviews will be required to fully understand the patient experience. Some 398 
of the studies included in this analysis had more complex tools to measure patients’ 399 
experience, such as Impact Event Score or Spielberger state trait anxiety inventory, 400 
however we did not include it in this analysis since they were. not used across all the 401 
studies. Moreover, we could not conclude whether the use of local anesthetic had any 402 
influence on the acceptability ratings of the Cytosponge test, as its use wasn’t routinely 403 
recorded and the data is missing for nearly half of the procedures.  404 
CONCLUSIONS 405 
 In conclusion, in this first review of clinical data on safety and acceptability of 406 
the Cytosponge, we have demonstrated that this device has a favourable safety and 407 
acceptability profile. The relative ease of administration and the higher safety profile 408 
as compared to endoscopy makes it a promising tool to be used in the primary care 409 
setting as a screening and surveillance test for esophageal disorders such as BE or 410 
EoE. Results from the ongoing BEST3 randomized trial (www.best3trial.org) will be 411 
critical prior to implementing the Cytosponge test for widespread use.  412 
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 516 
Table 1. Characteristics of Cytosponge studies included in the analysis 517 
Table 2. Demographic characteristics of patients from Cytosponge studies.  Values 518 
are numbers (percentages) unless stated otherwise 519 
Figure 1 520 
A. Cytosponge in gelatin capsule (right) and expanded (left).  521 
B, C. Haematoxylin and eosin (B) and trefoil-factor 3 (C) staining (20x) from patient 522 
with Barrett’s oesophagus showing columnar lined epithelium with goblet cells 523 
(arrowheads) (courtesy of dr Maria O’Donovan) 524 
D. Haematoxylin and eosin staining (200x) from patient with eosinophilic oesophagitis 525 
showing squamous epithelium with admixed eosinophils (arrowheads) 526 
Figure 2. The abrasion grading system after Cytosponge  527 
Figure 3. Cytosponge and endoscopy acceptability (per-procedure) 528 
Figure 4. Acceptability scores for the Cytosponge in different groups of patients (per-529 
procedure). 530 
Supplementary Table 1. Multivariate analysis model for failure of swallowing the 531 
Cytosponge 532 
Supplementary Table 2. Combined adverse events from all studies included in the 533 
analysis 534 
 535 
 536 
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Table 1. Characteristics of Cytosponge® studies included in the analysis 537 
 Study 1 
(BEST1) 
Study 2 
(BEST2) 
Study 3 
(BEST-Australia) 
Study 4 
(BEST2-RFA) 
Study 5 
(EoE) 
Country: UK UK Australia USA USA 
Disease: GERD GERD and BE GERD BE after RFA 
treatment 
EoE 
No. of patients 
(%): 
518 (21.4%) 1,498 (62.0%) 224 (9.3%) 76 (3.1%) 102 (4.2%) 
No. of 
Cytosponge® 
procedures 
(%): 
518 (19.4%) 1,752 (65.6%) 224 (8.4%) 76 (2.8%) 102 (3.8%) 
Time of 
recruitment: 
May 2008 – Dec 
2009 
July 2011 – 
Dec 2013 
May 2010 – 
August 2014 
October 2014 
–present 
(ongoing) 
December 
2012– present 
(ongoing) 
Inclusion 
criteria: 
• 50 – 70 yrs. 
• Prescription 
of acid 
suppressants 
for>3 months 
• Cases:  
BE under 
surveillance 
• Controls: 
GERD 
referred for 
endoscopy  
• 50 – 70 yrs. 
• Prescription 
of acid 
suppressants 
for>3 months 
• 18 – 80 
yrs. 
• BE with 
LGD / HGD 
after 
successful 
RFA 
treatment   
• 18 - 65 yrs.  
• EoE 
undergoing 
endoscopy 
25 
 
Setting: Primary care (12 
general 
practices) 
Secondary 
care (11 
hospitals) 
Secondary care  
(1 hospital) 
Secondary 
care (1 
hospital) 
Secondary 
care  
(2 hospitals) 
Time between 
Cytosponge® 
and 
endoscopy 
Up to 3 weeks Same day 
(within an 
hour) 
Same day Same day Same day (2 
hours prior to 
endoscopy) 
BE, Barrett’s esophagus; EoE, eosinophilic esophagitis; GERD, gastro-esophageal 538 
reflux disease; HGD, high-grade dysplasia; LGD, low-grade dysplasia; RFA, radio-539 
frequency ablation 540 
 541 
 542 
 543 
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Table 2. Demographic characteristics of patients from Cytosponge® studies.  Values 570 
are numbers (percentages) unless stated otherwise 571 
Characteristics All participants* Men** Women** 
Age (years) - median (IQR) 62 (54-68) 63 (54-69) 61 (54-67) 
Missing data 153 (6.3) 119 (12.8) 36 (2.4) 
Number of participants 
All studies 2,418 (100) 1,486 (61.5) 932 (38.5) 
Study 1 (BEST1 Study) 518 (21.4) 240 (46.3) 278 (56.7) 
Study 2 (BEST2 Study) 1,498 (62.0) 1,035 (69.1) 463 (30.9) 
Study 3 (BEST Study Australia) 224 (9.3) 95 (42.4) 129 (57.6) 
Study 4 (POST-RFA Study) 76 (3.1) 58 (76.3) 18 (23.7) 
Study 5 (EoE Study) 102 (4.2) 58 (56.9) 44 (43.1) 
Indication to Cytosponge® 
GERD 1,329 (55.0) 632 (47.6) 697 (52.4) 
BE 987 (40.8) 796 (80.6) 191 (19.4) 
EoE 102 (4.2) 58 (56.9) 44 (43.1) 
Body Mass Index (BMI, kg/m2) 
Median (IQR) 28.3 (25.3-31.6) 28.1 (25.6-31.0) 28.6 (24.8-33.1) 
Underweight (<18.5) 14 (0.6) 12 (85.7) 2 (14.3) 
Normal (18.5 to 24.9) 447 (18.5) 185 (41.4) 262 (58.6) 
Overweight (25.0 to 29.9) 853 (35.3) 236 (27.7) 617 (72.3) 
Obese (≥30.0) 739 (30.6) 313 (42.4) 426 (57.6) 
Missing data 365 (15.0) 186 (51.0) 179 (49.0) 
Waist to Hip Ratio*** 
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Median (IQR) 0.93 (0.87-0.98) 0.96 (0.92-0.99) 0.86 (0.81-0.91) 
Low Risk  786 (32.5) 622 (79.1) 164 (20.9) 
Moderate Risk  558 (23.1) 379 (67.9) 179 (32.1) 
High Risk  626 (25.9) 244 (39.0) 382 (61.0) 
Missing data 448 (18.5) 241 (53.8) 207 (46.2) 
Smoking Status 
Never 809 (33.5) 466 (57.6) 343 (42.4) 
Former 191 (7.9) 133 (69.6) 58 (30.4) 
Active 971 (40.2) 630 (64.9) 341 (35.1) 
Missing data 447 (18.5) 257 (57.5) 190 (42.5) 
Hiatus hernia 
Present 1,191 (49.3) 825 (69.3) 366 (30.7) 
Absent 1,025 (42.4) 538 (52.5) 487 (47.5) 
Missing data 202 (8.3) 123 (60.9) 79 (39.1) 
Previous endoscopic treatment (EMR, RFA, PDT) 
Yes 243 (10.0) 204 (84.0) 39 (16.0) 
No  2,175 (90.0) 1,282 (58.9) 893 (41.1) 
EMR, endoscopic mucosal resection; PDT, photo-dynamic therapy; RFA, radio-572 
frequency ablation;  573 
* The proportion (%) of patients from each group in the first column refers to the total 574 
participant number 575 
*  The proportion (%) of male and female patients refers to the number of participants 576 
from each group (first row), not the total participant number 577 
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** Waist to hip ratio was considered low risk for male <0.95 and female <0.80, 578 
moderate risk for male 0.95-1, female 0.81-0.85 and high risk for male >1, female >0.85 579 
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Figure 2  652 
 653 
31 
 
Figure 3654 
 655 
32 
 
Figure 4656 
 657 
 658 
 659 
 660 
 661 
 662 
 663 
 664 
 665 
 666 
 667 
 668 
 669 
 670 
 671 
 672 
 673 
 674 
33 
 
Supplementary Table 1. Multivariate analysis model for failure of swallowing the 675 
Cytosponge® 676 
* Since there were only 14 cases (0.6%) of underweight patients we did not include 677 
them in this analysis. 678 
BE, Barrett’s esophagus; CI, confidence interval; EoE, eosinophilic esophagitis; 679 
GERD, gastroesophageal reflux disease; OR, Odds ratio 680 
 681 
 682 
 683 
 684 
Factor OR 95% CI P value 
Gender 
Female (n=932) 1.00 - - 
Male (n=1,486) 1.08 0.61-1.90 P=0.79 
Study setting  
Primary care (n=518) 1.00 - - 
Secondary care (n=1,900) 5.13 1.48-17.79 P<0.01 
Body mass index* 
Normal BMI (n=447) 1.00 - - 
Overweight (n=854) 1.02 0.52-2.03 P=0.94 
Obese (n=739) 1.75 0.91-3.36 P=0.09 
Indication 
BE + EoE (n=987+102) 1.00 - - 
GERD (n=1,329) 0.63 0.35-1.14 P=0.13 
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Supplementary Table 2. Combined adverse events from all studies included in the 685 
analysis 686 
Serious Adverse Events Study Number of 
events 
Cytosponge®adverse events 
Cytosponge®detachment from string 
Laceration at the back of the throat 
BEST2-RFA 
BEST2 
1 
1 
Endoscopy adverse events 
Bleeding post-EMR and biopsy 
Chest pain post-EMR and syncope 
Post-RFA atrial fibrillation  
RFA-induced ulceration and bleeding 
Syncope 
Haematemesis from esophageal varices 
Epigastric pain  
Diarrhoea and coffee-ground vomiting post procedure 
Central chest pain and melena 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
BEST2 
1 
1 
1 
2 
1 
1 
1 
1 
1 
Total 12 
 687 
 688 
 689 
